Akèy › Kansè Endomèt › Alabama › Birmingham
Etid klinik pou Kansè Endomèt nan Birmingham, AL
16 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Birmingham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Ap rekriteFaz 3
- GSK Investigational Site, Birmingham
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ap rekriteFaz 3
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Ap rekriteFaz 2
- University of Alabama at Birmingham Cancer Center, Birmingham
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Birmingham
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Ap rekriteFaz 1/2
- University of Alabama_6th Ave, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- University of Alabama at Birmingham, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- University of Alabama Birmingham, Birmingham
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Children's Hospital of Alabama, Birmingham
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Alabama at Birmingham, Birmingham
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of Alabama at Birmingham, Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- ak 1 plis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ap rekriteFaz 2
- 004, Birmingham
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Ap rekriteFaz 1/2
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Birmingham
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Chicago, IL25 etid
- Columbus, OH25 etid
- Queens, NY25 etid
Lòt etid nan Birmingham
- Kansè (tout kalite)30 etid
- Kansè nan tete24 etid
- Obèsite23 etid
- Kansè ovè23 etid
- Kansè Poumon ki pa ti selil22 etid
- Leksemi mieloïd egi21 etid
- Myelom Miltip18 etid
- BPCO17 etid
- Maladi kadyovaskilè17 etid
- Sipwa16 etid
- Dyabèt Tip 216 etid
- Fibroz sistik16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.